Skip to lesson
OncoGuideeducationDiana’s wiki
THE EDUCATION LIBRARY

Epitope spreading

In one sentence

Epitope spreading is the extension of a detected immune response to additional epitopes beyond those initially targeted.

The intuition

An investigation can start with one clue and later uncover others. Immune recognition can similarly extend beyond the original target set. That is different from getting a larger response to the same targets.

“Newly detected” also differs from “newly created.” A response below an assay's detection limit can later become measurable.

How it works

Tumor injury can release additional antigens. Antigen-presenting cells may take up this material and help prime or expand cells recognizing other epitopes. This is a plausible route for broadening recognition; demonstrating the full causal chain requires more evidence than one positive follow-up assay.

Spreading can involve another epitope from the same source protein or an epitope from a different protein. A vaccine that directly includes A and B has not demonstrated spreading merely by eliciting responses to both. The newly recognized target needs to lie outside the initially targeted set for that claim.

For a T-cell experiment, define the peptide–human leukocyte antigen (HLA) pair and the functional assay. Compare baseline and follow-up samples, include background controls and distinguish altered recognition from simple expansion of the originally measured clone. A T-cell receptor (TCR) sequence alone does not identify its antigen specificity.

Vaccine exposure does not rewrite a mature T cell's receptor to match a new target. Expansion or recruitment of cells with other specificities can change the measurable response. Limited baseline sampling, cross-reactivity and accompanying treatments can complicate interpretation.

Why it matters in cancer

Broader recognition could help address heterogeneous tumors, but its detection is an immune finding. It does not automatically establish tumor control, prevention of recurrence or safety. Spreading to healthy self targets can have a different significance from spreading to tumor-specific targets.

Worked example

A fictional vaccine contains A and B. At follow-up, controlled assays detect responses to A, B and an unencoded target C. Baseline C was undetectable. This supports a newly detectable C response consistent with spreading.

Before attributing it to vaccination, ask whether the assay conditions were matched, whether C recognition is distinct from cross-reactivity, and whether other treatment or tumor injury occurred. Even if the interpretation holds, a separate outcome study is needed to establish clinical benefit.

Common confusions

  • A bigger A response is expansion, rather than spreading to B.
  • Newly detectable recognition does not prove that no relevant cell existed at baseline.
  • Multiple receptor sequences do not establish multiple antigen specificities without supporting experiments.
  • An immune biomarker is not a recurrence-prevention endpoint.

Sources and scope

Source-checked October 9, 2026. The example is fictional. The clinical study concerns a personalized long-peptide vaccine in melanoma; it does not establish the same result for every platform, cancer or treatment sequence. Expert and learner review remain pending.

Used in